Amplification and overexpression of the receptor tyrosine kinase ErbB2 occur in up to 30% of human breast cancers, and high ErbB2 levels are correlated with poor prognosis for breast cancer patients. In contrast to the epithelial growth factor receptor (ErbB1), ErbB2 is not downregulated by ligand-induced mechanisms. Here we show that flotillins are involved in the stabilization of ErbB2 at the plasma membrane. In SKBR3 breast cancer cells and breast cancer tissue, a positive correlation between flotillin and ErbB2 expression levels could be demonstrated. Moreover, the tissue microarray analyses of biopsies from 194 patients diagnosed with carcinomas of the breast showed that flotillin-2 emerged as a potential predictor of prognosis in breast cancer. Depletion of flotillin-1 and flotillin-2 leads to internalization and degradation of ErbB2. Furthermore, flotillin-1 and -2 were found to be in a molecular complex with ErbB2 and Hsp90. The depletion of one of these proteins results in disruption of this complex, followed by destabilization of ErbB2 at the membrane, and its internalization and degradation. As a consequence, ErbB2-triggered downstream signalling is inhibited. Our data demonstrate a novel mechanism for interfering with ErbB2 signalling, which potentially can have clinical impact.
INDRODUCTION
The ligand-less receptor tyrosine kinase ErbB2 is a preferred dimerization partner for the other members (EGFR/ErbB1, ErbB3 and ErbB4) of the EGFR (epithelial growth factor receptor) family. ErbB2 has been demonstrated to enable strong and constitutive signalling through different pathways that induce cell transformation, migration and proliferation. 2 In contrast to EGFR/ ErbB1, ErbB2 is endocytosed at a very slow rate and continuously recycled back to the cell surface. [3] [4] [5] The precise activation and deactivation of signalling cascades is a crucial cellular process and dysregulation can induce cancer development or progression. Thus, one of the challenges in cancer treatment is to promote silencing of signalling cascades. ErbB2 has been shown to be involved in the progression and development of a variety of different human tumours. Remarkably, in up to 20-30% of all human breast cancers, amplification and overexpression of ErbB2 can be found and high expression of ErbB2 has been demonstrated to be correlated with poor prognosis in breast cancer patients. [6] [7] [8] [9] The inhibition of oncogenic signalling triggered by ErbB2 can be achieved by different strategies, and administration of monoclonal antibodies (trastuzumab/Herceptin) became the first-line treatment in patients with ErbB2-overexpressing metastatic breast cancer. 6, 10 In breast cancer cells, ErbB2 is strongly concentrated at the plasma membrane and its stabilization at the membrane is mediated by Hsp90. Thus, another approach to abrogate oncogenic signalling is the induction of ErbB2 internalization and degradation by inhibition of Hsp90. Treatment with the Hsp90 inhibitor geldanamycin (GA) has been shown to induce ErbB2 downregulation. [11] [12] [13] Hsp90 is a known target in cancer therapy and GA analogues (for example, 17-AAG/tanespimycin) are used in the treatment and therapy of ErbB2-positive cancers in clinic. [14] [15] [16] To understand in greater detail how ErbB2 stabilization at the plasma membrane is mediated, we have investigated the involvement of the lipid raft-associated flotillins (flotillin-1 and -2) in this process. Flotillins, which are also termed reggies, 17 have been described to be localized mainly at the plasma membrane and in endosomal/ lysosomal compartments. [18] [19] [20] It has been demonstrated that flotillin proteins, among other functions, are involved in endocytic mechanisms and cellular trafficking processes. [21] [22] [23] In this study, we describe how flotillin-1 and -2 contribute to the stabilization of ErbB2 at the cell surface, and we show that ErbB2 is internalized and degraded by a GA-independent mechanism upon flotillin depletion. Importantly, flotillin and ErbB2 expression levels are positively correlated on a cellular level as well as in breast cancer tissue.
RESULTS

Association of flotillins with ErbB2
First, we analysed the cellular localization of ErbB2 and flotillins in SKBR3 breast cancer cells. We could show by confocal microscopy that flotillin-1 and -2 partially co-localize with ErbB2 at the plasma membrane ( Figure 1a ). In addition, interaction between flotillins and ErbB2 could be demonstrated by co-immunoprecipitation experiments, as immunoprecipitation of endogenous flotillin-1 or -2 resulted in pull down of ErbB2 (Figure 1b , quantification of pull down see Supplementary Figure S1a ). We next analysed the impact of flotillins on the internalization and subsequent degradation of ErbB2. As described above, ErbB2 is stably associated with the plasma membrane, but its internalization and degradation can be triggered by administration of the Hsp90 inhibitor GA. 11 The internalization process can easily be monitored by confocal microscopy, and visualized as a dotted staining of intracellular ErbB2 (Supplementary Figure S1b , lower panel). Western blot analysis of ErbB2 degradation and treatment of SKBR3 cells with 3 mM GA showed, as expected, a rapid decrease of ErbB2 levels within 2-4 h. However, protein levels of flotillin-1 or -2 and their intracellular localization were not affected by GA treatment (Supplementary Figures S1c and d) . Importantly, internalization of ErbB2 could be observed by confocal microscopy when cells were depleted for flotillin-1 or -2, in the absence of GA (Figures 2a and b) . The percentage of cells with internalized ErbB2 significantly increases after depletion of flotillins (Supplementary Figure S1e) . Interestingly, after flotillin depletion, ErbB2 is found to be localized in Lamp-1-positive vesicles (Supplementary Figure S1f) , supporting the data showing reduced levels of ErbB2 after flotillin knockdown. To investigate whether there is a correlation between the levels of membraneassociated ErbB2 and flotillin, we performed confocal microscopy studies in flotillin knockdown cells. Analysis of the fluorescence intensities of extracellular ErbB2 and total flotillin-1 or -2 showed approximately linear relationships (Figures 2c and d ) with good correlations, especially for flotillin-2 (flotillin-1: R ¼ 0.647, flotillin-2: R ¼ 0.855). To measure the direct uptake of ErbB2 after flotillin depletion, we labelled ErbB2 with specific antibodies on ice and incubated the cells at 37 1C for 30 min. Afterwards, cells were fixed and stained for ErbB2 and ErbB2 internalization was visualized by confocal microscopy ( Figure 2e ). As expected, control cells showed no uptake of ErbB2 within 30 min, whereas in GA-treated cells as well as in flotillin-depleted cells (Figure 2e , arrowheads), intracellular ErbB2 could be detected.
These data suggest that flotillins stabilize ErbB2 at the plasma membrane and thereby inhibit its degradation. Consequently, we examined by western blot analysis whether flotillin knockdown triggers ErbB2 degradation. For this purpose, SKBR3 were depleted of either flotillin-1 or -2 and subsequently incubated with or without 3 mM GA for 2 h (Figures 3a and b) . The results revealed that knockdown of flotillin-2 resulted in a stronger reduction of ErbB2 (B40%) than depletion of flotillin-1 (B20%), and the reduction after flotillin-2 depletion is comparable to the effect obtained upon treatment with GA alone.
To analyse in more detail the interaction of flotillins with ErbB2, we studied the association of ErbB2 with flotillin-1 or -2 in response to GA treatment. To achieve this, we performed an in situ proximity ligation assay (PLA) with the DuolinkII kit (Olink Bioscience, Uppsala, Sweden). This established method relies on antibody-based analysis and quantification of protein proximity by fluorescence microscopy. 24, 25 Briefly, after an amplification reaction, proteins of interest with a distance of less than 40 nm from each other can be visualized by fluorescence microscopy as distinct fluorescent dots, suggesting an association or complex of these proteins. By this assay, we could demonstrate a close proximity between flotillins and ErbB2 receptors (Figure 3c ). This proximity was disrupted upon GA treatment, as a significantly reduced level of flotillin/ErbB2 signals was observed in GA-treated cells (Figure 3d) . Importantly, the specific association of ErbB2 and flotillins is supported by a control experiment analysing proximity of ErbB2 with the membrane protein Par-2 (Supplementary Figure S2a) . No interaction of these proteins has been reported so far. However, by using PLA, a significant number of ErbB2/Par-2 signals per cell can be detected but the number of signals is not changed by GA treatment. This indicates that the ErbB2/Par-2 signals are probably due to the close spatial distribution of the two highly expressed membrane proteins rather than specific association of ErbB2 with Par-2. On the other hand, ErbB2/flotillin proximity is sensitive to GA treatment, indicating a specific association of ErbB2 and flotillins. Moreover, the number of flotillin-2/Par-2 proximity signals are 70% reduced compared with the number of ErbB2/Par-2 signals ( À GA).
Flotillins associate with Hsp90 in an ErbB2-dependent manner As already mentioned, Hsp90 is an essential component for the stabilization of ErbB2 at the plasma membrane. 26 Thus, we tested whether flotillins interact with Hsp90 or regulate Hsp90 protein levels. By co-immunoprecipitation, we could show that flotillins interact with Hsp90 ( Figure 1b) . These findings were in agreement with a partial co-localization of flotillins and Hsp90 at the plasma membrane, visualized by confocal microscopy (Figure 4a ). Based on these results, we investigated whether flotillins regulate Hsp90 protein levels and thereby stabilize ErbB2 receptors at the plasma membrane. However, depletion of flotillin-1 or -2 or flotillin double Figures S2c and d) .
After demonstrating that flotillin depletion triggers internalization and downregulation of ErbB2, we analysed whether flotillin depletion impairs the activation of ErbB2-induced signalling pathways. ErbB2 has been described as the only member of the ErbB tyrosine kinase receptor family without any known ligand. However, ErbB2 is a preferred dimerization partner for all of the other ErbB proteins. Dimer formation results in phosphorylation of the dimer partners and triggers the activation of signalling pathways. 27 Among several others, the two major pathways induced by ErbB dimers are the Ras/MAPK and the PI3K/Akt pathway, both involved in stimulating cell proliferation and tumour cell survival.
1,2 First, we analysed whether depletion of flotillin-1 or -2 changed the phosphorylation status of ErbB2 receptors. The activation status of ErbB2 was determined by quantification of p-ErbB2 (Tyr1248) levels by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Figure 5b ). The residue Tyr 1248 is the major phosphorylation site of ErbB2 and p-ErbB2 (Tyr1248) has been described as a predictor of poor prognosis in breast cancer. 28 Analysis of our data indicated that the levels of p-ErbB2 (Tyr1248) were significantly reduced after depletion of flotillins. Knockdown of flotillin-1 led to a 40% reduction, knockdown of flotillin-2 led to a 65% reduction in p-ErbB2 levels (Figures 5b and c) , and Flotillins stabilize ErbB2 at the plasma membrane S Pust et al administration of GA for 2 h resulted in B90% reduction of the pErbB2 levels. Interestingly, treatment of cells with GA or depletion of flotillins resulted in a significantly stronger reduction of p-ErbB2 levels compared with the reduction of total ErbB2. Furthermore, we investigated the influence of flotillin-induced ErbB2 downregulation on Akt signalling. ErbB2 is able to bind to PI3K, inducing phosphorylation of PI(4,5)P2 and the subsequent recruitment of Akt kinase, the main effector of PI3K. Upon activation, Akt phosphorylates several downstream targets that lead to tumour cell survival and anti-apoptotic signalling. 29, 30 By measuring the phosphorylation of Akt upon GA treatment, a B90% reduction in p Akt levels was observed, whereas total Akt levels were not significantly changed. Cells depleted of flotillin-2 showed a 40% reduced phosphorylation of Akt (Figures 5d and e) . In contrast to the data obtained with flotillin-2, only a slight but not significant reduction in the p-Akt levels was observed upon flotillin-1 depletion.
High expression of flotillin-2 correlates with poor prognosis in breast cancer To verify the physiological role of flotillins as regulators of the receptor tyrosine kinase ErbB2, and to determine whether flotillin levels are clinically correlated with ErbB2 expression, we examined how flotillin levels correlate with ErbB2 levels in breast cancer tissues. To this end, we used immunohistochemistry to analyse flotillin and ErbB2 levels in tissues from 194 patients diagnosed with carcinomas of the breast (stage I/II). The samples were scored and a correlation coefficient was calculated as described in the Materials and Methods. The analysis (Figures 6a-c, Supplementary  Figure S3 and Supplementary Table S1) showed a correlation of flotillin-1 and flotillin-2 levels (R ¼ 0.746, Po0.001, n ¼ 130), of flotillin-1 and ErbB2 levels (R ¼ 0.431, Po0.001, n ¼ 140) and of flotillin-2 and ErbB2 levels (R ¼ 0.307, Po0.001, n ¼ 133). Moreover, our study demonstrate that the expression of flotillin-2 is correlated with survival time (log-rank, P ¼ 0.0349; Figure 6d ), but that is not the case for flotillin-1 (P ¼ 0.427; Figure 6e ). Thus, high expression of flotillin-2 was associated with poor prognosis and reduced survival time, and it emerges as a potential predictor of relapse in breast cancer.
DISCUSSION
The most important finding in the present article is that stabilization of ErbB2 at the cell surface is dependent on functional flotillin proteins. This stabilization is mediated by a complex containing ErbB2, Hsp90 and flotillin proteins. Depletion of or functional interference with one of these components disrupts this complex, and results in destabilization, internalization and degradation of ErbB2, thereby interfering with ErbB2 signalling. This is reflected by reduced phosphorylation of ErbB2 and reduced activation of the ErbB2 effector Akt.
We have here demonstrated that depletion of flotillins induced the internalization and degradation of ErbB2, and depletion of flotillin-2 resulted in a stronger reduction of ErbB2 levels than seen 
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Protein expression levels in ErbB2-depleted cells. SKBR3 cells were treated with siRNA oligonucleotides targeting ErbB2 and incubated for 3 days, cells were lysed and analysed by SDS-PAGE. ErbB2 levels were significantly reduced (B70% reduction compared with control cells), but protein levels of flotillin-1 or -2 and Hsp90 were not influenced. GAPDH levels were determined as loading controls.
after depletion of flotillin-1. In agreement with this observation is the finding that Akt phosphorylation was reduced after knockdown of flotillin-2 but not after flotillin-1 depletion, and that only flotillin-2 can serve as a prognostic marker for breast cancer at early stages. The differences seen with flotillin-1 and flotillin-2 may reflect the slightly different nature, different membrane-anchoring properties, intracellular localization and functions of flotillin-1 and -2, as described earlier by us and other groups. 22, 31, 32 Moreover, a stronger reduction of ErbB2 levels was obtained when GA treatment was combined with depletion of flotillin-2. This indicates that flotillin-2 depletion and GA treatment can have synergistic effects that might be of therapeutical interest. In line with a potential role of flotillins as stabilizers of proteins at the membrane, flotillin-1 has been reported to stabilize the level of caveolin-1 in intestinal epithelial cells, 33 and caveolins by themselves are involved in membrane organization. As the ErbB2/Hsp90 interaction is impaired by flotillin depletion, and also the association between flotillin and Hsp90 is affected upon depletion of ErbB2, the data suggest that there is a molecular complex containing ErbB2, Hsp90 and flotillin proteins. However, future studies are required to characterize other proteins in this complex that may participate in the regulation and stabilization of ErbB2 receptors.
Inhibition of Hsp90 has been shown to induce rapid ubiquitination of ErbB2 followed by receptor downregulation. 34, 35 Indeed, in our experiments, GA treatment results in strong receptor ubiquitination (Supplementary Figure S2e) . However, no or very little ErbB2 ubiquitination can be observed after flotillin depletion. In contrast to the short-term effect of GA, depletion of flotillins occurs over a period of 3 days. Thus, it seems likely that most of the internalized ErbB2 is already degraded at that time. This is supported by our data showing reduced ErbB2 levels after flotillin depletion and less internalized ErbB2 compared with GA treatment. On the other hand, we cannot exclude the possibility that flotillin depletion leads to ErbB2 internalization by a mechanism independent of ubiquitination. However, further studies are necessary to elucidate this process.
Data from two very recent publications indicate that in HeLa cells flotillin-1 has a functional role in receptor tyrosine kinase signalling, especially in the activation of MAP kinase signalling and the regulation of FGF signalling. 36, 37 However, in the SKBR3 cells studied here, we found that Akt phosphorylation is reduced upon depletion of flotillin-2, but not after flotillin-1 knockdown. Thus, receptor tyrosine kinases or receptor tyrosine kinase-mediated signalling pathways might be regulated by flotillins in different ways and/or in a cell type-specific manner. Moreover, it is possible that the different signalling pathways triggered by ErbB2 are regulated by either flotillin-1 or flotillin-2. Nevertheless, the reduced p-ErbB2 and p-Akt levels triggered by flotillin Flotillins stabilize ErbB2 at the plasma membrane S Pust et al knockdown support our hypothesis of a flotillin-mediated stabilization of ErbB2. ErbB2 is known to be associated with poor prognosis in breast cancer, but also flotillins have been described to be associated with tumorigenesis. 38, 39 However, this is the first study determining the functional role of both flotillin proteins on the regulation of ErbB2. We demonstrated that the expression of flotillin-2 is correlated with survival time. Thus, high expression of flotillin-2 is associated with poor prognosis and reduced survival time, and it emerges as a potential predictor of relapse in breast cancer. Up to 70% of all breast tumours are oestrogen receptorpositive, and oestrogen receptor expression is an important prognostic factor. Interestingly, it has been reported that flotillin-2 also interacts with oestrogen receptors, 40 indicating a significant impact of flotillin-2 function on breast cancer development. On the other hand, based on our tissue microarray studies, flotillin-1 did not emerge as a prognostic marker for relapse in breast cancer, which did not confirm the study of Lin et al. 39 However, in their study, more than 40% of the analysed breast cancer tissue was stage III/IV; whereas in our study, only material of early stages (stage I/II) was used to get a high prognostic relevance. Therefore, it might be possible that flotillin-1 affects tumour progression only at later stages. Further studies are needed to get a detailed picture of the function of flotillins in tumour development.
In conclusion, this is the first demonstration of a positive correlation between flotillin and ErbB2 levels in cultured breast cancer cells as well as in patient material. Moreover, flotillin-2 expression levels seem to correlate with poor prognosis in breast cancer, indicating that flotillin-2 might be a prognostic biomarker for breast cancer. As it has been found that ErbB2-overexpressing tumours are more likely to be resistant to treatment with tamoxifen and standard chemotherapy, an antibody-based (trastuzumab/Herceptin) therapy has become the clinical first-line treatment in patients with ErbB2-overexpressing metastatic breast cancer. 6, 10 However, even in combination with other chemotherapeutical medications, more than 70% of patients with ErbB2-overexpression show no response to the treatment. 41 Thus, by targeting flotillin expression, new strategies in cancer treatment can be developed.
MATERIALS AND METHODS
Antibodies and other reagents HEPES, bovine serum albumin, n-octylglucopyranoside and rabbit antiflotillin-2 antibody (F1680) were purchased from Sigma-Aldrich (St Louis, MO, USA). For western blot analysis, anti-flotillin-1/-2 antibodies were from BD Bioscience (St Jose, CA, USA), the rabbit anti-flotillin-1 antibody was a gift from Dr G van der Goot (EPFL, Lausanne, Switzerland), anti-ErbB2 (29D8), anti-Akt and anti-p-Akt Ser473 was from Cell Signaling Technologies (Boston, MA, USA), anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase, ab9484) was from Abcam (Cambridge, UK), anti-p-ErbB2
Tyr1248 (Ab-18) and anti-ErbB2 (Ab-17) was purchased from Thermo Scientific (Waltham, MA, USA) and fluorescently labelled secondary antibodies from Li-Cor Biosciences (Lincoln, NE, USA) (IRDyes) were used for western blot analysis. Anti-ErbB2 (Santa Cruz Biotechnology (Santa Cruz, CA, USA), 9G6), antiHsp90 (Sigma-Aldrich, H-114), anti-flotillin-1 (van der Goot) and anti-flotillin-2 (Sigma-Aldrich, F1680) and secondary antibodies from Jackson ImmunoResearch (Suffolk, UK) were used for confocal fluorescence microscopy. Protein concentrations in the lysates were determined by the BCA protein assay (Pierce, Rockford, IL, USA) or with the use of bovine serum albumin as the standard by using the NanoDrop 2000 spectrophotometer (Thermo Scientific) Cell culture and transfections SKBR3 cells were grown under 5% CO 2 in Dulbecco's modified Eagle's medium (Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin, and 2 mM L-glutamine. For siRNA transfection, cells were seeded out in six-well plates at a density of 2 Â 10 5 cells/well, 24 h before transfection. siRNAs targeting non-overlapping parts of the mRNA sequence were used for flotillin-1 and -2, as described before. 22 For the depletion of ErbB2, a pool of four different siRNA oligonucleotides with the sequences 5 0 -UGGAAGAGAUCACAGG UUA-3 0 , 5 0 -GAGACCCGCUGAACAAUAC-3 0 , 5 0 -GGAGGAAUGCCGAGUACUG-3 0 and 5 0 -GCUCAUCGCUCACAACCAA-3 0 (Dharmacon, RNAi Technologies, Lafayette, CO, USA) has been used. To reduce unspecific off-target effects, the constructs were ordered as ON-TARGETplus oligos from Dharmacon RNAi Technologies, as negative controls non-targeting oligos were used. For siRNA transfection, the cells were seeded out without antibiotics, grown for 24 h and transfected by using Lipofectamine RNAiMax transfection reagent (Invitrogen) according to the manufacturer's procedure. After 4 h of transfection, the medium was changed to complete growth medium containing serum and antibiotics, and the cells were grown for 3 days before experiments were started. For rescue experiments, siRNA-resistant flotillin-1 and -2 (DNA 2.0, Menlo Park, CA, USA) were cloned into the mammalian expression vector pcDNA3 (Invitrogen). SKBR3 cells were seeded and transfected and incubated for 2 days with siRNA oligos (as described above) and subsequently transfected and incubated for 24 h with 1 mg of siRNA-resistant flotillin-1 or -2 or empty pcDNA3 vector by using FuGene6 (Roche Applied Science, Basel, Switzerland), as described elsewhere. 22 Protein extraction and western blot
The cells were washed in cold phosphate-buffered saline (PBS) and lysed in lysis buffer containing 0.1 M NaCl, 10 mM Na 2 HPO 4 , 1 mM EDTA, 1% Triton X-100, 60 mM n-octylglucopyranoside, pH 7.4 and supplemented with Complete protease inhibitors and PhosSTOP (Roche Diagnostics, Basel, Switzerland). The lysate was cleared by centrifugation (8000 r.p.m., 10 min) and proteins were separated by SDS-PAGE under reducing conditions. After blotting onto a PVDF membrane (Immobilon-FL, Millipore, Billerica, MA, USA), the membrane was blocked by air drying. Thereafter, the membrane was re-wet in PBS with 0.5% Tween-20 (PBS-T) (or in Trisbuffered saline (TBS) with 0.5% Tween-20 for phospho-specific antibodies) and incubated with the primary antibody in 1% BSA in PBS-T overnight at 4 1C. After extensive washing in PBS-T (or TBS-T), LI-CORE infrared dye secondary antibodies (Li-Cor Biosciences) were applied, and the bands were detected and quantified using the Odyssey imaging system (Li-Cor Biosciences).
Confocal fluorescence microscopy and imaging
Cells were grown on glass coverslips and transfected with siRNA oligonucleotides targeting flotillin-1 or flotillin-2 or non-targeting control oligos and incubated for 3 days. Subsequently, either the cells were fixed for 15 min with 4% paraformaldehyde and permeabilized for 2 min with 0.1% Triton X-100/PBS or fixed and permeabilized for 7 min with ice-cold methanol, before immunostained with appropriate antibodies. Fluorophore-labelled secondary antibodies used for confocal studies were obtained from Jackson ImmunoResearch Laboratories. The cells were mounted in Mowiol or Prolong Gold containing DAPI for nuclear staining (Molecular Probes, Invitrogen, Paisley, UK) and examined by a laserscanning confocal microscope LSM 710 or LSM 780 (Carl Zeiss, Jena, Germany) and a PlanApo 63 Â /1.4 NA oil-immersion objective. Images were prepared and analysed with the LSM Image Browser software (Carl Zeiss) or ImageJ software.
In situ PLA The in situ PLA (Olink Bioscience) was used to detect flotillin/ErbB2, flotillin/ Hsp90 and ErbB2/Hsp90 associations. The assay is based on oligonucleotide-conjugated PLA probes, containing secondary antibodies directed against primary antibodies for either flotillin-1/-2, ErbB2 or Hsp90. Annealing of the probes occurs when the target proteins are in close proximity, which then initiates the amplification. The amplicons can be detected by fluorescence microscopy in a quantifiable manner. For this assay, SKBR3 cells were seeded in six-well plates on coverslips and either transfected with siRNA oligos and/or pretreated with 3 mM GA for 2 h, as indicated in the figure legends. Cells were washed, fixed and permeabilized as described in the section above. Antibodies against ErbB2 (1:200, Santa Cruz Biotechnology, 9G6), Hsp90 (1:100, Santa Cruz Biotechnology, H-114), flotillin-1 (1:2000, van der Goot) and flotillin-2 (1:200, Sigma-Aldrich, F1680) were used as primary antibodies and the assays were performed as described in the manufacturer's manual. Slides were mounted with Duolink Mounting Medium (Olink Bioscience) and samples were observed by fluorescence microscopy with a LSM 780 confocal microscope (Carl Zeiss). The number of dots were calculated by ImageJ software and normalized to control conditions.
Immunoprecipitation
Cell lysates from non-treated SKBR3 cells were made in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40, 60 mM n-octylglucopyranoside) supplemented with Complete protease inhibitors and PhosSTOP (Roche Diagnostics), and cleared by centrifugation (8000 r.p.m., 10 min). Protein G-sepharose beads (Amersham Biosciences, Piscataway, NJ, USA) in PBS were incubated with the desired antibody for 2 h before washing with PBS. Beads pre-bound to antibody were mixed with the lysate and incubated at 4 1C overnight. After extensive washing, associated proteins were eluted by boiling at 95 1C for 5 min, separated by SDS-PAGE, and blotted onto a PVDF membrane (Immobilon-FL, Millipore). The membrane was processed and the bands detected as described for western blot analysis.
Immunohistochemistry and scoring of tissue samples
The patient material consists of 194 patients diagnosed with carcinomas of the breast (Stage I/II) at the Norwegian Radium Hospital in the period [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] [1994] . To obtain a material well suited to test potential prognostic markers, the patients either had relapse or cancer-related death within 5 years after prognosis, or disease-free survival for at least 10 years. From each patient, two cylindrical cores from formalin-fixed and paraffinembedded tumour tissue were taken, and all the cores were collected in three tissue microarrays as described elsewhere. 42 The use of the material has been approved by the South East Region Committee for Research Ethics in Norway (REK 6.2008.1000). For immunohistochemistry analysis, antibodies were purchased from Sigma (anti-flotillin-1, HPA1392, 1:1500 and anti-flotillin-2, HPA 1396, 1:4000) and from Novocastra (anti-c-erbB-2, NCL-CB11, 1:700). Sections (3 mm) of the tissue microarrays were stained with an AutostainerLink48 (DAKO) with high pH antibody retrieval, peroxidase block, 30 min antibody incubation, EnVision FLEX þ mouse linker and HRP/DAB visualization.
The membrane in situ expression of the three proteins was scored by a pathologist according to the proportion and intensity categories proposed by Allred et al. 43 Following this system, the intensity was scored as 0: no staining; 1: weak staining; 2: intermediate staining; 3: strong staining. The proportion was scored as 0:0% tumour cells with membrane staining; 1:0p1/100; 2:1/100p1/10; 3:1/10p1/3; 4:1/3p2/3; 5:2/3p100%. For the correlation analysis, a total score (TS) was calculated by adding the values for proportion and intensity. For the survival analysis, the total scores were further categorized in two different ways: total score ¼ 0-6, low expression; total score ¼ 7-8, high expression. In the analysis, some cores were excluded owing to loss of the core during processing, too poor quality to be scored, only benign tissue left in the core or lack of correspondence between the score for intensity and proportion (for example, proportion ¼ 0 and intensity ¼ 2).
Statistics
Values of three or more experiments were given as mean±s.e.m. A P-value of 0.05 or less was considered to be statistically significant and determined by the Student's t-test or Mann-Whitney Rank Sum test, as indicated in the figure legends. For all statistical measurements, a minimum of 50 cells per condition and experiments has been analysed. For immunohistochemistry analysis, Pearson correlation coefficients were calculated between the total scores of the three different proteins. We have made Kaplan-Meier-like curves on categorized total scores to illustrate differences between groups, although the study design imply that this will not be proper survival curves for Stage I/II breast cancer patients. The Mantel-Cox log-rank test was used for testing equality of survival distributions. An event was defined as relapse or cancer-related death. The statistical analyses were performed in SPSS 18.
